We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 05. 07. | 장 마감 후 (AMC) | $-0.28 | — | — | $0 | — | 예정 |
Consensus PT $4 · 1 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2025. 12. 19. | HC Wainwright & Co. | — | 의견 유지 | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2025. 11. 19. | B of A Securities | — | 의견 유지 | Buy → Buy | — | B of A Securities: Buy |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
| # | 기관 | 운용 형태 | 보유 주식 | 평가액 | 비중 | 변화율 | 포지션 |
|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 14,483 | $9.18M | 0.00% | — | 신규 편입 |
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. In addition, it develops WTX-1011, a conditionally activated INDUCER T cell engager molecule that targets STEAP 1 for prostate cancer, as well as WTX-2022 that targets CDH6 for ovarian and kidney cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
Stored first · Google News · Yahoo Finance (English)
What's Behind the Recent Insider Selling at Werewolf Therapeutics (HOWL) - Kavout
What's Behind the Recent Insider Selling at Werewolf Therapeutics (HOWL) Kavout
Werewolf Therapeutics director Luke Evnin sells $66,200 in shares - Investing.com
Werewolf Therapeutics director Luke Evnin sells $66,200 in shares Investing.com
Director-linked funds trim Werewolf (NASDAQ: HOWL) stake via 141K-share sale - Stock Titan
Director-linked funds trim Werewolf (NASDAQ: HOWL) stake via 141K-share sale Stock Titan
[144] Werewolf Therapeutics, Inc. SEC Filing - Stock Titan
[144] Werewolf Therapeutics, Inc. SEC Filing Stock Titan
MPM-linked funds tied to Werewolf (NASDAQ: HOWL) sell 191,762 shares under plan - Stock Titan
MPM-linked funds tied to Werewolf (NASDAQ: HOWL) sell 191,762 shares under plan Stock Titan
Werewolf Therapeutics stock (US95075A1079): insider share sales and sharp price slide unsettle biote - AD HOC NEWS
Werewolf Therapeutics stock (US95075A1079): insider share sales and sharp price slide unsettle biote AD HOC NEWS